FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089225531> ?p ?o ?g. }

• W3089225531 endingPage "276" @default.
• W3089225531 startingPage "270" @default.
• W3089225531 abstract "Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially serious bleeding condition in the fetus/newborn. FNAIT is usually considered as the platelet counterpart of hemolytic disease of the fetus and newborn. In FNAIT, maternal alloantibodies against paternally inherited platelet antigens traverse the placenta and cause thrombocytopenia in the fetus/newborn. The most common and most serious cases of FNAIT among white people are caused by alloantibodies against the human platelet antigen 1a (HPA-1a), which is absent in 2.3% of women. Today, there is no screening for FNAIT, and for this reason, FNAIT is not suspected until an otherwise healthy child, born at term, presents with thrombocytopenia. Clinical management of subsequent pregnancies at risk of FNAIT is mostly based on the obstetric history. During the last 5 decades, hemolytic disease of the fetus and newborn caused by antibodies against RhD has successfully been prevented by administration of hyperimmune anti-D IgG drug products to RhD-negative women after delivery of an RhD-positive child. Similarly, a hyperimmune anti-HPA-1a IgG (NAITgam) is under development for the prevention of HPA-1a immunization and FNAIT. If NAITgam becomes licensed for FNAIT prophylaxis and national health authorities decide to include FNAIT screening in their antenatal health care programs, it will be necessary to improve today's tools for assessing the risk of FNAIT. Although the primary risk factor for HPA-1a immunization is platelet type HPA-1bb, not all HPA-1a-negative women develop anti-HPA-1a. The women who are HLA-DRB3:01:01 negative (72%) only rarely develop anti-HPA-1a, and for those few who become HPA-1a immunized, it is quite rare to have a child with severe thrombocytopenia. Determination of fetal HPA-1 type is important because 15% of HPA-1a-negative women will carry an HPA-1a-negative fetus and therefore not be at risk of FNAIT. The severity of FNAIT seems to be associated with the level of anti-HPA-1a. Hence, in Norway, for example, an Ab threshold of 3 IU/mL is used to distinguish between low- and high-risk pregnancies. The current review will discuss to what extent these analyses, as well as determination of subtypes of anti-HPA-1a (anti-β3, anti-αIIbβ3, and anti-αvβ3) and Fc core fucosylation of anti-HPA-1a IgG, can be used as risk stratification tools." @default.
• W3089225531 created "2020-10-01" @default.
• W3089225531 creator A5003869180 @default.
• W3089225531 creator A5063306960 @default.
• W3089225531 date "2020-10-01" @default.
• W3089225531 modified "2023-10-13" @default.
• W3089225531 title "Fetal and Neonatal Alloimmune Thrombocytopenia—New Prospects for Fetal Risk Assessment of HPA-1a–Negative Pregnant Women" @default.
• W3089225531 cites W1481853573 @default.
• W3089225531 cites W1512319198 @default.
• W3089225531 cites W1563891443 @default.
• W3089225531 cites W1574741273 @default.
• W3089225531 cites W1783267328 @default.
• W3089225531 cites W1910709306 @default.
• W3089225531 cites W1962969173 @default.
• W3089225531 cites W1975507131 @default.
• W3089225531 cites W1976432358 @default.
• W3089225531 cites W1978766025 @default.
• W3089225531 cites W1979648611 @default.
• W3089225531 cites W1990741626 @default.
• W3089225531 cites W2009720281 @default.
• W3089225531 cites W2015623521 @default.
• W3089225531 cites W2027415471 @default.
• W3089225531 cites W2034193052 @default.
• W3089225531 cites W2034786850 @default.
• W3089225531 cites W2044052575 @default.
• W3089225531 cites W2058222232 @default.
• W3089225531 cites W2058727179 @default.
• W3089225531 cites W2065163701 @default.
• W3089225531 cites W2079568377 @default.
• W3089225531 cites W2084136419 @default.
• W3089225531 cites W2088563278 @default.
• W3089225531 cites W2092625089 @default.
• W3089225531 cites W2095256989 @default.
• W3089225531 cites W2101783052 @default.
• W3089225531 cites W2103233292 @default.
• W3089225531 cites W2110320870 @default.
• W3089225531 cites W2123388271 @default.
• W3089225531 cites W2136547534 @default.
• W3089225531 cites W2158608092 @default.
• W3089225531 cites W2160388832 @default.
• W3089225531 cites W2238663835 @default.
• W3089225531 cites W2309767301 @default.
• W3089225531 cites W2413722883 @default.
• W3089225531 cites W2414436823 @default.
• W3089225531 cites W2583039933 @default.
• W3089225531 cites W2891529979 @default.
• W3089225531 cites W2899530537 @default.
• W3089225531 cites W2904983456 @default.
• W3089225531 cites W2911387941 @default.
• W3089225531 cites W2932314172 @default.
• W3089225531 cites W2963863869 @default.
• W3089225531 cites W2997767677 @default.
• W3089225531 cites W2998564674 @default.
• W3089225531 cites W3044843104 @default.
• W3089225531 cites W4253361598 @default.
• W3089225531 cites W83303467 @default.
• W3089225531 doi "https://doi.org/10.1016/j.tmrv.2020.09.004" @default.
• W3089225531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33039264" @default.
• W3089225531 hasPublicationYear "2020" @default.
• W3089225531 type Work @default.
• W3089225531 sameAs 3089225531 @default.
• W3089225531 citedByCount "10" @default.
• W3089225531 countsByYear W30892255312021 @default.
• W3089225531 countsByYear W30892255312022 @default.
• W3089225531 countsByYear W30892255312023 @default.
• W3089225531 crossrefType "journal-article" @default.
• W3089225531 hasAuthorship W3089225531A5003869180 @default.
• W3089225531 hasAuthorship W3089225531A5063306960 @default.
• W3089225531 hasBestOaLocation W30892255311 @default.
• W3089225531 hasConcept C131872663 @default.
• W3089225531 hasConcept C147483822 @default.
• W3089225531 hasConcept C172680121 @default.
• W3089225531 hasConcept C203014093 @default.
• W3089225531 hasConcept C2778430493 @default.
• W3089225531 hasConcept C2779234561 @default.
• W3089225531 hasConcept C2779989375 @default.
• W3089225531 hasConcept C54355233 @default.
• W3089225531 hasConcept C71924100 @default.
• W3089225531 hasConcept C86803240 @default.
• W3089225531 hasConceptScore W3089225531C131872663 @default.
• W3089225531 hasConceptScore W3089225531C147483822 @default.
• W3089225531 hasConceptScore W3089225531C172680121 @default.
• W3089225531 hasConceptScore W3089225531C203014093 @default.
• W3089225531 hasConceptScore W3089225531C2778430493 @default.
• W3089225531 hasConceptScore W3089225531C2779234561 @default.
• W3089225531 hasConceptScore W3089225531C2779989375 @default.
• W3089225531 hasConceptScore W3089225531C54355233 @default.
• W3089225531 hasConceptScore W3089225531C71924100 @default.
• W3089225531 hasConceptScore W3089225531C86803240 @default.
• W3089225531 hasIssue "4" @default.
• W3089225531 hasLocation W30892255311 @default.
• W3089225531 hasLocation W30892255312 @default.
• W3089225531 hasOpenAccess W3089225531 @default.
• W3089225531 hasPrimaryLocation W30892255311 @default.
• W3089225531 hasRelatedWork W121096383 @default.
• W3089225531 hasRelatedWork W1481853573 @default.
• W3089225531 hasRelatedWork W2103233292 @default.
• W3089225531 hasRelatedWork W2341709626 @default.

• next